Chipotle Falls Most Since 2012, Signals Trouble for Fast-Casual

Summary

Bloomberg Intelligence Podcast — Episode Summary Episode: "Chipotle Falls Most Since 2012, Signals Trouble for Fast-Casual"
Date: October 30, 2025
Hosts: Scarlet Fu and Paul Sweeney
Key Guests: Michael Halen (Bloomberg Intelligence Restaurant/Food Service Analyst), Geetha Ranganathan (Media Analyst), Robert Langreth (Healthcare Reporter)

---

Episode Overview

This episode covers three major stories in business and markets:

• Chipotle’s significant stock decline and what it signals for the fast-casual dining sector
• Comcast’s continuing struggles and what its recent earnings report says about media, cable, and theme parks
• Major M&A drama in the pharmaceutical sector with Novo Nordisk’s bid for Medcera and the competitive landscape in weight loss drugs

The tone throughout is analytical but brisk, with hosts challenging guest narratives and providing both market and consumer perspective.

---

1. Chipotle’s Troubles: Industry or Self-Inflicted?

[01:49 – 06:22]

Key Points & Insights

• Chipotle's Stock Plunge:

  • Chipotle’s shares dropped 15.7% after a disappointing earnings release, summing to about a 40% decline YTD.
  • The company cited broader macroeconomic pressures and consumer pullback, especially in the DC area (possibly linked to government shutdowns).

• Michael Halen’s Analyst Take:

  • Halen pushes back on Chipotle’s narrative, stating:

    “Chipotle is trying to blame the macro, but...this is largely self inflicted in our view.” ([02:22])

  • Compared Chipotle to peers like Shake Shack and Domino’s, who posted strong earnings and didn’t report similar pressures.

• Demographics & Spending:

  • Chipotle’s claim of exposure to low-income consumers or Gen Z is challenged.
  • Survey data shows Gen Z is actually outspending other cohorts with expectations to increase spend next year ([02:22 – 02:54])

• Portion Sizes & Value Confusion:

  • There’s inconsistency in Chipotle’s messaging:

    “They said we’re priced 20 to 30% below peers. And at the same time...survey data was showing that some people thought their food was way too expensive. So which one is it?” — Michael Halen ([04:53])

• Competitor Pricing & Value Promotions:

  • Shake Shack’s 1-3-5 value offer ($1 drinks, $3 fries, $5 shakes) boosted traffic by 400 basis points week-over-week.

    “Customers right now do want value and Chipotle doesn’t really have it on its menu.” — Michael Halen ([05:52])

Memorable Quotes

• “If you don’t even know what your problem is, how are you supposed to fix it?” — Michael Halen ([04:53])
• “When they started giving you more stuff in your taco, I didn’t need three. I only order two now because they overflow it.” — Paul Sweeney ([06:05])

---

2. Comcast’s Struggles & Media Sector Realities

[09:05 – 15:40]

Key Points & Insights

• Comcast’s Earnings – The Big Picture

  • Despite a slight improvement in subscriber losses, broadband competition is fierce and profit (EBITDA) fell 4%.
  • Promotional activity (five-year price locks, free mobile lines) helps slow customer churn but bites into margins ([09:23] – [10:33]).

• Media Assets & Structural Challenges

  • Comcast’s cable arm generates 80-85% of EBITDA but faces mounting telecom threats. NBCUniversal (media) brings about 15%.
  • The conglomerate structure yields a valuation “discount” — the different segments weigh each other down ([11:32]).

• Potential M&A with Warner Bros Discovery

  • The company needs a transformative move; Warner Bros Discovery is a possible target, but an expensive and risky one.
  • Investor skepticism lingers due to past acquisitions (e.g., overpaying for Sky).

    “Being a buyer of media assets is generally not a good allocation of capital.” — Paul Sweeney ([12:24])

  • Geetha sees strategic value if executed well:

    “They can extract tremendous synergies...there is a good fit in terms of IP...Peacock very heavy on sports, HBO very heavy on scripted originals...” ([13:03])

• Peacock’s Struggles & Theme Park Success

  • Subscriber growth is subscale and below estimates; profitability remains elusive.
  • Theme park business (Universal) is booming (revenue up 19%) with big investments in new attractions delivering results ([15:08]).

Memorable Quotes

• “Comcast saw this coming...this whole thing with the experience economy. And they’re riding that wave in a big way.” — Geetha Ranganathan ([15:08])
• “They need to do something transformative. I think Warner Brothers is definitely the solution. The question is can they afford to get into a bidding war with Paramount?” — Geetha Ranganathan ([11:32])

---

3. Pharmaceutical M&A: Weight Loss Drug Frenzy

[18:25 – 23:57]

Key Points & Insights

• Novo Nordisk, Pfizer, and Medcera: The Bidding War

  • Novo Nordisk launched a surprise, aggressive bid for Medcera, which had already accepted Pfizer’s offer.
  • Both Novo and Pfizer are desperate to catch up to Eli Lilly, which is dominating weight loss (and diabetes) drugs with strong sales ([19:01]).
  • Medcera’s appeal: a next-gen injectable targeting new metabolic pathways with potentially fewer side effects.

• Deal Mechanics and Legal Maneuvering

  • Medcera’s shareholders now have a superior bid; Pfizer has four days to counter.
  • Legal drama looms, with Pfizer claiming Novo’s bid is “reckless and illusory,” alleging attempts to sidestep antitrust scrutiny ([21:22]).
  • Regulatory approval and geopolitical context (US vs. Danish firm) may factor into the outcome ([21:49]).

• Industry Stakes & Market Projections

  • Eli Lilly’s blockbuster drugs (Mounjaro and Zepbound) delivered $10B this quarter; they’re likely to become the world’s best-selling drugs soon ([23:11]).
  • The market for these obesity medications is projected at $100 billion/year.

Memorable Quotes

• “This was their deal to try to like get back in...Now Novo’s coming in over the top suddenly with this super aggressive, hyper aggressive deal, you know, and that Pfizer is calling reckless and illusory.” — Robert Langreth ([19:01])
• “Drug companies do that when they don’t have the internal goods.” — Robert Langreth ([22:42])
• “Together, this quarter, [Eli Lilly's drugs] had over $10 billion in sales. It’s crazy. This is going to be like, together it’s going to be the best selling drug in the world next year.” — Robert Langreth ([23:11])
• “Game changer...Another one, a pill that grows hair in men.” — Paul Sweeney, in jest ([23:49])

---

Timestamps—Key Segments

• Chipotle and Fast-Casual Analysis: [01:49 – 06:22]
• Comcast Earnings and Media Sector: [09:05 – 15:40]
• Pharma M&A (Novo Nordisk, Pfizer, Medcera): [18:25 – 23:57]

---

Style and Tone

• Analytical, sometimes skeptical and humorous.
• Hosts actively challenge official company narratives and draw comparisons to industry peers.
• Frequent use of memorable anecdotes and sharp quotes.

---

Summary Usefulness:
This episode gives a sharply focused look at the interplay between company strategy and broader market forces—useful for investors, analysts, and business watchers wanting in-depth sector insight not just headline news.

Transcript

[Paul Sweeney]

The FIFA World Cup 26 is coming to North America. Get closer to where business meets the beautiful game with a hospitality package featuring premium seats and entertainment. Get closer to wins on and off the pitch. Register [e-mail] Interest the Chase Inc. Business Premier card is a painful card with flexibility made for business owners who make things happen. Earn a total of 2.5% cash back on every purchase of $5,000 or more, plus earn unlimited 2% cash back on every other purchase, giving you unlim unlimited earned potential to invest cash back into your business. Inc. Business Premier is part of a suite of credit cards from Chase for Business designed to meet your needs every step along the way. Learn [e-mail] businesscard Chase for Business make more of what's yours Accounts subject to credit approval restrictions and limitations apply. Cards are issued by JPMorgan Chase Bank NA member FDIC Hiscock Small business Insurance Knows there is no business like your business. Across America, over 600,000 small businesses, from accountants and architects to photographers and yoga instructors, look to Hiscox Insurance for protection. Find flexible coverage that adapts to the needs of your small business with a fast, easy online', @hiscox.com that's his there's no business like small business. Hiscox Small Business Insurance.

[Bloomberg Intelligence Podcast Host]

Bloomberg Audio Studios Podcasts Radio news. You're listening to the Bloomberg Intelligence Podcast. Catch us live weekdays at 10am Eastern on Apple CarPlay and Android Auto with the Bloomberg Business app. Listen on demand wherever you get your podcasts or watch us live on YouTube.

[Paul Sweeney]

Chipotle Mexican Grill I was just there yesterday. Love it. It's my kind of my once a week thing.

Was it crowded?

Yeah, yeah, it's always crowded when the schools get out because all the kids come in there and then that's a joke.

They're big fans.

Yeah. Anyway, it was good but apparent finally not so good in the quarter. They had some disappointing results. Their guidance was a little cautious here and the Stock is down 15.7% today, down about 40% year to date. Michael Halen joins us, senior restaurant and food service analyst for Bloomberg Intelligence. Mike, is this a Chipotle thing? Is this a fast service, quick service restaurant thing? What is going on there?

[Michael Halen]

Now listen, there, there is, you know, some other companies are talking about a little bit of a pullback here in October. I think a big part of it is is really around the D.C. metropolitan area and has to do with the government shutdown. But this is, you know, Chipotle is trying to blame the macro, but you know, this is Largely self inflicted in our view. I mean, if you look at the other earnings that have been released, Shake Shack this morning had a great print. Restaurant brands, which owns, you know, Burger King, Tim Hortons, Popeyes had a very good print. Domino's, Chili's are crushing it right now. So you know, for them to come out and blame low income consumers, which they have a very low exposure to, as well as Gen Z, which, you know, there's some anecdotal stuff out there about how Gen Z employment isn't great. But you know, the survey data that we see is showing that Gen Z is spending, spending more than other age cohorts and expect to spend more next year. So it's really, I think, largely self inflicted.

[Paul Sweeney]

I love the pushback against the narrative that Chipotle is peddling here. Having said that, you're seeing shares of Sweetgreen and Kava Group decline in tandem in sympathy with Chipotle. What does this mean? Whether it's a macro backdrop story that Chipotle is, you know, putting the blame on or a Chipotle specific problem. What does this mean for how it prices its food? Up until now it's been moving forward with price increases.

[Robert Langreth]

Yeah.

[Michael Halen]

So this is, this is one of the things that kind of really got me going on this call yesterday and then calls in the past as well. So you know, last year, I would say about 15 months ago, a little more 16 months ago, there was, it went viral that their portion sizes were getting smaller. Right. And they made an investment to increase the portion sizes, which they've done. Right. So there was a problem last year. Then on a call earlier this year, there's, they were talking about how much value they have and we think we're still a great value out. Value is not our issue. Then they came back on this call and they spoke out of both sides of their mouth. They said we're priced 20 to 30% below our peers. And at the same time they said their survey data was showing that some people thought their expood was way too expensive. So which one is it?

[Paul Sweeney]

Right.

[Michael Halen]

Like if you don't even know what your problem is, how are you supposed to fix it?

[Paul Sweeney]

Interesting. So what are some of the competitors doing in terms of price increases to, I don't know, cover the cost of tariffs or just general rising costs of B4? What are some of the competitors doing in the industry?

[Robert Langreth]

Mike?

[Michael Halen]

Yeah, I think the biggest problem here is that they don't have any everyday value on their menu. And I understand their reluctance to go there, but I mean Customers want to see it. And I, I think Shake Shack today, which is, has been one of our, our favorite names this year, talked about how they've, they have this new 1, 3, $5 offer, right? So $1 drinks, $3 fries, $5 shakes, right. Like it's not like a crazy discount and it's, it's items that are typically pretty good margin, right. But they talked about how they switch the focus to that and value and it boosted traffic 400 basis points in this week over the week prior.

[Paul Sweeney]

Wow.

[Michael Halen]

So customers right now do want value and Chipotle doesn't really have it on its menu.

[Robert Langreth]

All right.

[Paul Sweeney]

God's, you know, lipstick your ears or whatever that thing.

And we have the anecdotal evidence that you just provided.

My anecdotal evidence is when they started giving you more stuff in your, in my taco, I didn't need three. I only order two now because they overflow it.

So they're like crazy.

They want that. Michael Halen, Senior Restaurant Analyst, Bloomberg Intelligence Pulling no punches on the folks at I love it.

I love it. He had the alternate take.

Exactly. And he often has that take and he often is contentious on earnings conference calls. I've heard myself back in the day, I used to listen in on some of those. Stay with us. More from Bloomberg Intelligence coming up after this.

The FIFA World Cup 26 is coming to North America next summer. It's the ultimate celebration of sports and culture and an opportunity to elevate your company. Get closer to where business meets the beautiful game with a premium hospitality package. Build partnerships in the best seats and suites. Achieve goals over world class food and beverage. Get closer to wins on and off the pitch. Register [e-mail] Interest running small and medium.

[Amazon Ads Announcer]

Sized businesses is hard work. Business owners need to be sure that their ads are working just as hard as they do. Amazon Ads allows businesses to track and optimize campaigns for better ROI from their marketing. With Amazon ads, you can be more sure that your marketing is reaching relevant audiences during premium content and shows they're actually watching. Trillions of browsing, shopping and streaming insights help you optimize your campaigns in real time and measurement tools show you what's working the hardest. Gain the edge with Amazon Ads when.

[Paul Sweeney]

You own your own business, you own every decision. Now own the car that rewards you for it. The Chase Sapphire Reserve for Business Card brings the best Sapphire Reserve benefits to business owners who expect hard working rewards. Designed to meet the needs of business owners at scale, this Pay in Full card elevates your travel experience and offers premium benefits and value toward business services that can take your business to the next level. Sapphire Reserve for business provides over $2,500 in annual value. Fuel your business and maximize rewards with 8x points on all purchases through Chase Travel, 3x points on social media and search engine advertising, annual partnership credits and more. Make every journey more rewarding with a $300 annual travel credit and access to a network of airport lounges. Whether you're looking for pre flight productivity or time to rest and recharge. Chase Sapphire Reserve for business with over $2,500 in annual value, it's the card that gives back all you put in. Learn [e-mail] ReserveBusiness Chase for Business make more of what's yours Accounts subject to credit approval restrictions and limitations apply. Cards are issued by JPMorgan Chase Bank NA member FDIC.

[Bloomberg Intelligence Podcast Host]

You're listening to the Bloomberg Intelligence Podcast. Catch us live weekdays at 10am Eastern on Apple CarPlay and Android Auto with the Bloomberg Business app. Listen on demand wherever you get your podcasts or watch us live on YouTube.

[Paul Sweeney]

Comcast reported some earnings here. Stocks down 3%, down 26% year to date. Tough, tough sledding for these cable companies here. Let's go to Geetha Ranganathan. She covers all the media stuff for Bloomberg Intelligence. And Geetha, what's the takeaway from the Comcast earnings here? Another tough quarter?

[Geetha Ranganathan]

Yes, Paul, another tough quarter for Comcast and we suspect it's going to be that way for a while for these cable companies. They've been having a lot of competition in their broadband business. Remember broadband? Comcast is the largest broadband provider in the United states, has over 30 million subscribers, but they've been losing customers at an increasing pace even though this quarter actually subscriber losses came in slightly better than what we had feared. Comcast is doing everything that they can do to get subscribers to stay on their platforms, just given the very, very intense competition from the telcos. That's working. But you know, it's come at a cost. So they you know, we've we're seeing quite a bit of pressure on the ARPU side as well, as we saw a decline in their ebitda of almost 4% and they warned that we're going to continue to see EBITDA declines for many more quarters to come.

[Paul Sweeney]

So this idea of using price lock guarantees and bundled plans to slow down to stem the bleeding of folks who are cutting the cord now that it started this, it has to kind of stay with it, right? You can't you can't stop that promotional activity.

[Geetha Ranganathan]

You cannot. Scarlett, you're right. And you know these price logs are five year price logs. They're giving away mobile lines for free. I mean that's definitely having some impact. So we did see, you know, the subscriber numbers come out much better. In fact, the mobile, the number of wireless customers that they added was record the highest ever that they've had. But obviously it is going to continue to put a lot of pressure on the top line as well as on the bottom line. And there's no way they can stop it. They have to keep going with it, which means that the EBITDA pressure is going to be sustained.

[Paul Sweeney]

So that's a reminder to me, Paul, that I have to call up Verizon and some of the other providers to argue down whatever package I have right now.

Absolutely.

[Michael Halen]

Are you like first order business?

[Paul Sweeney]

It works, Geetha. The fundamentals are one thing, but probably the big, big thing overhanging this story right now, the Comcast is what are they going to do as it relates to the M and A front and Warner Brothers discovery here, where's the narrative there right now?

[Geetha Ranganathan]

They need to do something, Paul. And I mean you just said this stock is down 26% year to date. It's down over 30% for the past year. And they have some great media assets. They have NBCUniversal, but it's just not enough. They're getting punished, both sides. So they own CA broadband assets which makes up about 80, 85% of EBITDA. Again, cable is under tremendous pressure because of this telecom competition. Those multiples are at around 5 to 6x media, which is the NBC assets brings in about 15% of their EBITDA. They have some great assets but again, they have this funny thing going on with the conglomerate discounts. They're not able to catch a break either on the media side or on the cable side. They need to do something transformative. I think Warner Brothers is definitely the solution. The question is can they afford to get into a bidding war with Param? And I'm not sure if they can afford it.

[Paul Sweeney]

All right, Keith is my favorite Wall street cable analyst out there. My number two is Craig Moffitt at Moffitt Nathanson. He's out with a note today saying and he's covered the stock forever. And one of the big bear cases for Comcast is that they are a serial acquirer. Every five years they feel the need to go out and buy something big. And the problem is, as Geetha well knows, being A buyer of media assets is generally not a good allocation of capital. It's not good here. So, so GitHub, there's a concern here that, you know, maybe it's just not going to be worth it if they go out and do another big deal. They're going to lever up their balance sheet. They're going to have years and years of integration risk and that could be a big long term drag on the stock. How do you, how do you counter that?

[Geetha Ranganathan]

Yeah, that's always kind of been the, you know, that's always spooked investors, Paul. I mean, you know very well what they did a few years ago. They overpaid for Sky a 15x multiple when they should have probably paid like 6 or 7. So they do have this kind of propensity to go out, pay the big doll. Warner Brothers, I think there was a little bit of a different story for them. They have, they can extract tremendous synergies, I think from the asset. There's a really good fit in terms of ip. We know that they already license, you know, Harry Potter and a lot of those other, you know, Warner Brothers IP into their parks. So there is a good fit. You know, there's a lot that can be done. On the streaming side, again you look at Peacock very heavy on sports, HBO very heavy on scripted originals. I think it's really a nice complementary portfolio. I think this time it could be a little bit different. But again, who knows?

[Paul Sweeney]

Yeah, some big questions and of course they need to figure out their strategy on this. You mentioned Peacock. What is the latest with Peacock? Because subscriber growth when we cared about it and you know, that was a while ago because now we care about profitability, rose 14%. That missed analysts estimates. Even after raising prices that missed analyst estimates. And it's not making money, is it?

[Geetha Ranganathan]

It's not, it's not Scarlet and it's not going to for, you know, for the foreseeable future. So they are definitely a subscale service. They have just about, you know, 42, 43 million subscribers. Again you're comparing that to Netflix which has about 310, 315 million. So just a huge catch up game that that Peacock has to play. They do have some really good programming though, you know, especially when you look at sports. They just recently acquired the rights to NBA, so, so we do have that now. You know, they have the NFL. So there is quite a bit of good sports property. I just don't know what they can do to necessarily up those subscriber numbers which is why they absolutely need something transformative from a, from a, from an M and a perspective.

[Paul Sweeney]

Geeta, before we let you go, what about the theme park business? Universal, obviously a huge attraction in California and in Orlando the revenue rose 19%. Is that in good shape and what might that tell us about what Disney tells us?

[Geetha Ranganathan]

It's in very good shape and which is why we're, you know, we have more and more confidence in the theme park business. Comcast saw this coming. They knew that this was, you know, the next big thing, you know, this whole thing with the experience economy. And they're riding that wave in a big way. We saw them open Epic Universe earlier this year. They've opened some other new attractions in Texas and in Las Vegas. So there, and there's a big park that's coming near London in about four or five years. So they're making big investments. It's paying off. And you know, just like Comcast, we're pretty bullish on, on the Disney business as well.

[Paul Sweeney]

Yeah, theme park business. Who would have thunk it? Geetha Ranganathan, thank you so much for joining us. Geetha is the media analyst at Bloomberg Intelligence. Stay with us. More from Bloomberg Intelligence coming up after this.

[Amazon Ads Announcer]

Running small and medium sized businesses is hard work. Business owners need to be sure that their ads are working just as hard as they do. Amazon ads allows businesses to track and optimize campaigns for better ROI from their marketing. With Amazon ads, you can be more sure that your marketing is reaching relevant audiences during premium content and shows they're actually watching. Trillions of browsing, shopping and streaming insights help you optimize your campaigns in real time and measurement tools show you what's working the hardest. Gain the edge with Amazon Ads when.

[Paul Sweeney]

You own your own business, you own every decision. Now own the card that rewards you for it. The Chase Sapphire Reserve for Business card brings the best Sapphire Reserve benefits to business owners who expect hard working rewards. Designed to meet the needs of business owners at scale, this painful card elevates your travel experience and offers premium benefits and value toward business services that can take your business to the next level. Sapphire, reserved for business, provides over $2,500 in annual value. Fuel your business and maximize rewards with 8x points on all purchases through Chase Travel, 3x points on social media and search engine advertising, annual partnership credits and more. Make every journey more rewarding with a $300 annual travel credit and access to a network of airport lounges. Whether you're looking for pre flight productivity or time to rest and recharge. Chase Sapphire Reserve for business with over $2,500 in annual value, it's the car that gives back all you put in. Learn [e-mail] ReserveBusiness Chase for Business, make more of what's yours. Accounts subject to credit approval restrictions and limitations apply. Cards are issued by JPMorgan Chase Bank, NA member FDIC. Did my card go through? Oh, no.

Your small business depends on its Internet, so switch to Verizon business and you could get LTE business Internet starting at $39 a month when paired with select Business Mobile plans. That's unlimited data for unlimited business.

[Robert Langreth]

There we go.

[Paul Sweeney]

Get the Internet you need at the price you want. Verizon Business Starting Price for LTE Business Internet 25 Mbps Unlimited Data Plan with.

Select Verizon Business smartphone plan.

Savings terms apply.

[Bloomberg Intelligence Podcast Host]

You're listening to the Bloomberg Intelligence podcast. Catch us live weekdays at 10am Eastern on Apple Car Play and Android Auto with the Bloomberg Business app. Listen on demand wherever you get your podcasts or watch us live on YouTube.

[Paul Sweeney]

The frenzied M and A taking place in the pharmaceutical sector. Let's dig into that right now because Novo Nordisk, who is kind of the OG when it comes to weight loss drugs, is now making an aggressive, unsolicited bid for Med Sarah, which had already agreed to a deal with Pfizer. Let's bring in Robert Langworth, Bloomberg News health care reporter on the latest here. And I mean, this is kind of the highest level of corporate drama given that Novo Nordisk is moving very aggressively. Just step back for a moment here. Who is scrambling more right now? Who is more, you know, I don't want to say desperate, but you know, kind of desperate here to do something.

[Robert Langreth]

Yeah, right now Eli Lilly is dominant in the weight loss area. It just reported great sales of its weight loss and diabetes drugs. And Novo was, you know, was the first move originally, but it's been falling behind it as a new CEO. You know, some of their drugs fed less than stellar trial results. So it's really trying to get back into the area. And Pfizer too. Pfizer's been trying to doesn't have anything weight loss, trying to break in, had some trials of pills that didn't work out so well. And this was like, and so now this was their deal to try to like get back in with a new thing that was injectable but had less nausea and vomiting. But now Novo's coming in over the top suddenly with this super aggressive, hyper aggressive deal, you know, and that Pfizer is calling Reckless and illusory. And, you know, it's gonna be a very dramatic next few days to see what happens.

[Paul Sweeney]

This is cool. I mean, this is like barbarians at the gate kind of thing, people fighting over it. So tell us about Mitzerah. I mean, what do they got that these people are going crazy?

[Robert Langreth]

Yeah. So they have a new, you know, the existing drugs. They target things like GLP1, which you've heard of, and also Zepbound. This drug also targets another related hormone called Gypsy gip. And Medcera has something targeting something called amylin. It's kind of another related hormone. And it's had some early trial results were good. And the hope is that this one, it's also injectable, will have less of kind of the nausea and vomiting. That's a very kind of common side effect of the existing drugs. And so that's gotten people excited. It's only early stage results. But, you know, Pfizer really doesn't have anything with bc. Do they really want something? And so this was something that, by all accounts, they were very excited about. And now they're going to be under great pressure to, you know, either try to coming over the top with something or maybe, like, work their angles in the Trump administration to try to see if, like, the Nova deal could be blocked. But it's going to be super dramatic.

[Paul Sweeney]

Right, because regulators would need to approve whatever happens. But before we even get there, Med Sarah has to decide which offer it's going to accept. Did it already accept Pfizer's bid, which I believe maxes out at $70 a share.

[Robert Langreth]

Yes. Of Pfizer. You know, they announced the Pfizer deal, I think this was last month. And now there's Nova's coming over the top of this bid, and Metsera has already said, hey, this new one is superior. And apparently Pfizer has four days to come up with a better offer. Now we'll have to see what's going to happen. Could there be legal action? Pfizer could pursue legal action, they're already saying.

[Paul Sweeney]

On what grounds?

[Robert Langreth]

Well, they're already saying this is reckless and illusory. There's some very complicated conditions that Nova offer. Some of Mitzerah's shareholders will get the money before the antitrust approval happens, as I understand it. So it's a very kind of complicated structure that Pfizer is claiming that's been engineered this way to try to avoid antitrust scrutiny and saying this isn't right. But Netcera, meanwhile, is saying, hey, we got a superior deal. What are you going to do for us? Pfizer.

[Paul Sweeney]

Pfizer is a US Company. Novo Nordisk is a Danish company. Does that play into it at all?

[Robert Langreth]

Well, some of the people I was talking to said Pfizer is one of the company. The big companies, one handful of big companies have made kind of pricing deals with the Trump administration already to avoid tariffs. Right. So it seems, you know, seems to have good relations there. So, you know, could, you know, could it work its context in the Trump administration, you know, to get them to, you know, give indications that this deal is going to have a hard time going through on antitrust grounds if Novo does it? Because Novo is already the number two weight loss company. Company right now with no is being.

[Paul Sweeney]

Led by a new CEO. He's a lifer from the company, but he's trying to make some big changes, put his own stamp on the company and he's moving very aggressively. What has he been doing lately? What is his mandate? What is his philosophy here?

[Robert Langreth]

Yeah, I don't know a lot about him. You know, he's really new. But clearly what I can say is that, you know, this is a sign that they are not confident, you know, in what they have internally. They have to come in this hyper aggressive deal. This is a sign that they kind of, it's kind of acknowledgement they're falling behind Eli Lilly and they need to come up with new and better drugs and have to get that externally. Drug companies do that when they don't have the internal goods.

[Paul Sweeney]

So Lilly, just to wrap it up here, Lilly had some pretty darn good numbers, right?

[Robert Langreth]

Yeah. So they have two drugs. Tirzepatide, it's the same drug. The diabetes version is called Mounjaro and the obesity one is called Zepbound. Together this quarter they had over 10 billion in sales. It's crazy. This is going to be like, together it's going to be the best selling drug in the world next year.

[Paul Sweeney]

Just wait till they get into a.

[Robert Langreth]

Pill for Both ones are up over 100% and that's with, you know, with increasing pricing discounts, it still is up over 100%. So they are becoming just totally dominant.

[Paul Sweeney]

But they keep talking about this being $100 billion a year industry, right?

[Robert Langreth]

Yeah. There's like huge potential numbers out there. You know, we'll see whether they achieve that. Oh, and Lilly's also ahead and coming out of the weight loss pill that's there.

[Paul Sweeney]

Game changer, you know, it's me.

Another one. A pill that grows hair in men.

All right. They figure that out Lilly. Get to work on that.

Yes.

Robert Langright, the Bloomberg News health care reporter, on the drama that we're seeing in the health care series, the pharmaceutical space as well as Eli Lilly's earnings.

[Bloomberg Intelligence Podcast Host]

This is the Bloomberg Intelligence Podcast available on Apple, Spotify and anywhere else you get your podcast. Listen live each weekday 10am to noon Eastern on Bloomberg.com, the iHeartRadio app, TuneIn and the Bloomberg Business app. You can also watch us live Every weekday on YouTube and always on the Bloomberg Terminal.

[Paul Sweeney]

Bloomberg Daybreak is your best way to get informed first thing in the morning, right in your podcast feed. Hi, I'm Karen Moscow.

[Michael Halen]

And I'm Nathan Hager. Each morning we're up early putting together.

[Paul Sweeney]

The latest episode of Bloomberg Daybreak US Edition.

[Michael Halen]

It's your daily 15 minute podcast on the latest in global news, politics and international relations.

[Paul Sweeney]

Listen to the Bloomberg Daybreak US Edition podcast each morning for the stories that matter with the context you need.

[Michael Halen]

Find us on Apple, Spotify or anywhere you listen.